The global In Vivo Contract Research Organization (CRO) Market is growing rapidly and is expected to continue doing so in the coming years. The market was worth USD 5.35 billion in 2022 and is projected to reach USD 9.84 billion in 2032, growing at a CAGR of 7%.

The main drivers of this growth are the increasing need for outsourcing of preclinical research operations by pharmaceutical and biotechnology companies, as well as the adoption of advanced technologies for efficient research and development outcomes. The market provides services such as toxicology testing, pharmacokinetics and pharmacodynamics, bioanalysis and drug metabolism, and efficacy and safety testing.

Get a free sample PDF of the report, visit @

https://www.reportsanddata.com/download-free-sample/6428

In vivo CROs conduct preclinical research on the pharmacological characteristics of pharmaceuticals and their safety using various animal models, including mice, rats, rabbits, canines, and non-human primates. The advantages of in vivo CROs in terms of cost and timeliness have contributed to the trend of outsourcing preclinical research activities.

Key players in the In Vivo Contract Research Organization (CRO) Market –

  • Charles River Laboratories International, Inc.
  • LabCorp
  • Covance Inc.
  • PRA Health Sciences
  • Envigo
  • WuXi AppTec
  • Syngene International Limited
  • Pharmaron Beijing Co., Ltd.
  • ICON plc
  • Concept Life Sciences

Pharmaceutical businesses are increasingly outsourcing their operations to cut overall costs and speed up the drug development process. Furthermore, the development of targeted medicines and increasing emphasis on personalized medicine are expected to drive market revenue growth.

To know more about the latest insights of the report, visit @

https://www.reportsanddata.com/request-latest-insight/6428

 However, the strict laws controlling the use of animal models for drug development, expensive prices for in vivo CRO services, and lack of standardization in preclinical research operations, are major factors that could restrain market revenue growth.

The service types into which the in vivo CRO market has been divided are pharmacology, toxicology, efficacy, and safety. In 2021, the market was dominated by the pharmacology category due to the rising need for in vivo research to assess the pharmacological qualities of potential new drugs before they are authorized for clinical testing.

The toxicology segment is expected to have the fastest revenue growth in the forecast period due to the increasing importance of in vivo toxicity testing to ensure the security of novel drug candidates. During the forecast period, the efficacy and safety segments are also anticipated to experience considerable expansion due to the growing emphasis on personalized medicine and the requirement for efficacy studies to assess the efficiency of novel medication candidates in certain patient populations.

Geographically, North America controlled a sizable revenue share of the in vivo CRO market in 2021 due to the region's abundance of pharmaceutical and biotech firms, the welcoming regulatory climate, and the rising expenditure in research & development activities.

The end-use segments of the in vivo CRO market are Contract Research Organizations (CROs), Academic & Government Research Institutes, Pharmaceutical & Biotechnology Companies, and Others. The Pharmaceutical & Biotechnology Companies section had the highest revenue share of these groups in 2021 due to their substantial investments in R&D. For the purpose of conducting preclinical investigations for drug discovery and development, these businesses need in vivo CRO services. During the projection period, the Academic & Government Research Institutes segment is anticipated to have considerable revenue growth.

Overall, it is anticipated that the in vivo CRO market would expand significantly over the course of the forecast period due to the rising demand for in vivo studies to assist pharmaceutical development and regulatory approvals. The requirement for extensive safety and efficacy testing, as well as the expanding emphasis on personalized medicine, are additional factors that are anticipated to fuel the in vivo CRO market's expansion in the upcoming years.

Request a customized copy of the report @

https://www.reportsanddata.com/request-customization-form/6428

Thank you for reading our report. To inquire about customization or any query about the report, please get in touch with us. Our team will make sure the report is best suited to your needs.  

About Reports and Data 

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact:

John W, Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: [email protected]
LinkedIn | Twitter | Blogs